Considering comorbidity in managing rheumatic diseases going where trials cannot go.docVIP

Aletaha and D?rner Arthritis Research Therapy 2011,13:116 /content/13/3/116 EDITORIAL Considering comorbidity in managing rheumatic diseases: going where trials cannot go Daniel Aletaha* and Thomas D?rner It remains a great challenge to treat the complexity of drug (NSAID) treatment in patients with liver or systemic rheumatic diseases in clinical practice. In contrast to what one may think, these challenges are not cardiovascular disease, but in theory one could also think about potential synergisms of treating the index disease so much related